WuXi AppTec Co, Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene ...

WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the Ohio-based regulatory consulting firm NAMSA. The deal includes facilities in ...

Contract research organisation (CRO) NAMSA has acquired the US-based medical device testing operations of WuXi AppTec to strengthen its medtech clinical research testing capabilities. The deal ...

Fans don't think that the two colors in the Super Bowl 2025 logo — red and green — are a coincidence Skyler Caruso is a Writer and Reporter of PEOPLE Digital Entertainment. She joined PEOPLE ...

Chinese contract drug maker WuXi AppTec rose 7.0% in afternoon trade in Hong Kong, on track for its largest daily percentage gain since early December. Its sister company WuXi Biologics rose 4.7% ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

DelveInsight's Biologics Drug Substance Manufacturing Market Insights report provides the current and forecast market ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

In March, WuXi AppTec split from the Biotechnology Innovation Organisation (BIO) after the trade organisation voiced its support for the legislation. The Act’s backers - Representatives Raja ...